Gene therapy appraisals may limit new drugs in Canada

Canada's separate environmental protection oversight unnecessarily delays development and approval

Gene therapy appraisals may limit new drugs in CanadaBy Nigel Rawson and Mackenzie Moir The Fraser Institute The federal government plans to move ahead with major revisions in regulations governing the tribunal that sets ceiling prices for new prescription drugs in Canada. Revisions include: replacing countries with relatively higher drug prices with lower price countries in the international price-comparison analysis'; enforcing hard thresholds…

Denying hope and health to Canadians with rare disorders

Manufacturers must overcome several federal government hurdles before patients have access to drugs

Denying hope and health to Canadians with rare disordersThe federal government has proposed major changes to the role of the Patent Medicine Prices Review Board (PMPRB), whose primary function is to ensure that maximum Canadian prices for patented medicines aren’t excessive. The changes, due to come into effect in 2019, will impact all new drugs but especially those for patients with rare disorders…

Ottawa blocking Canadians’ access to innovative drugs

Health Canada’s revisions to the drug-pricing review board will delay or prevent access to new drugs

Ottawa blocking Canadians’ access to innovative drugsEveryone wants affordable medicines, but are Canadians prepared to accept the trade-off of even longer delays before we can access innovative drugs? Last May, then-federal health minister Jane Philpott announced proposed changes to the Patented Medicine Prices Review Board (PMPRB) designed “to protect Canadians from excessive drug prices.” PMPRB is an independent federal organization that,…